Table 1 Baseline characteristics of JIA study population and healthy controls
JIA patients (n = 130) | Control group (n = 62) | p-value | |
|---|---|---|---|
Sex, female (n(%)) | 103.0 (79.0) | 31.0 (50.0) | < 0.001 |
Age (yr), mean (SD) | 11.0 (5.0) | 10.0 (5.0) | 0.567 |
Weight (kg), mean (SD) | 39.0 (18.0) | 40.5 (20.9) | 0.616 |
Height (cm), mean (SD) | 138.0 (25.0) | 142.5 (28.0) | 0.731 |
BMI (kg/m2), mean (SD) | 19.0 (4.0) | 19.7 (4.7) | 0.273 |
BMI SDS, mean (SD) | -0.03 (1.0) | 0.05 (1.3) | 0.659 |
ANA positive(n(%)) | 100.0 (77.0) | - | |
RF positive (n(%)) | 3.0 (2.0) | - | |
HLA-B27 positive(n(%)) | 2.0 (1.5) | - | |
ESR (mm/h), median (range) | 8.0 (2.0–88.0) | 7.0 (2.0–31.0) | 0.142 |
CRP (mg/l), median (range) | 0.8 (0.1–32.0) | 0.5 (0.1–9.9) | 0.046 |
Hb (g/dl), mean (SD) | 13.0 (1.1) | 13.2 (1.2) | 0.134 |
PLT/ µl, median (range) | 299500.0 (151000.0-524000.0) | 289500.0 (176000.0-522000.0) | 0.945 |
WBC/µl, median (range) | 6735.0 (3249.0-13160.0) | 7095.0 (4390.0-14420.0) | 0.150 |
Neutrophils/µl, median (range) | 3005.0 (3075.0-9370.0) | 3255.0 (1430.0-7850.0) | 0.116 |
Lymphocytes/µl, median (range) | 2675.0 (760.0-6580.0) | 2810.0 (1070.0-7400.0) | 0.547 |
Ferritin (ng/mL), median (range) | 22.3 (1.0-133.0) | 37.1 (6.0-110.0) | 0.003 |
Albumin (g/dl), mean (SD) | 4.3 (0.3) | 4.3 (0.2) | 0.852 |
CAR, median (range) | 0.2 (0.0-7.8) | 0.1 (0.0-2.3) | 0.046 |
PLR, median (range) | 110.3 (52.6-319.7) | 108.7 (46.1-259.8) | 0.404 |
NLR, median (range) | 1.1 (0.1–4.5) | 1.1 (0.3–4.2) | 0.347 |
Age at disease (JIA) onset, median (range) | 4.6 (1.0–15.0) | - | |
Disease duration (yr), mean (SD) | 5.0 (4.0) | - | |
JIA categories (n(%)) | - | ||
• Oligoarticular | 75.0 (58.0) | ||
• Extended oligoarticular | 19.0 (15.0) | ||
• Polyarticular | 27.0 (21.0) | ||
• Psoriasic | 8.0 (6.0) | ||
• Enthesitis-Arthritis | 1.0 (1.0) | ||
Previous therapy (n(%)) | - | ||
• No | 18.0 (14.0) | ||
• Methotrexate | 64.0 (49.0) | ||
• Etanercept | 4.0 (3.0) | ||
• Adalimumab | 1.0 (1.0) | ||
• MTX + Etanercept | 16.0 (12.0) | ||
• MTX + Adalimumab | 6.0 (5.0) | ||
• MTX + Etanercept + Adalimumab | 1.0 (1.0) | ||
• NSAIDs | 17.0 (13.0) | ||
• Tocilizumab | 3.0 (2.0) | ||
• Intra-articular corticosteroids | 92.0 (71.0) | ||
Number of previous intra-articular infiltrations, median (range) | 1.0 (0.0–15.0) | - | |
Lag time to MTX initiation (yr), median (range) | 0.3 (0.0-9.4) | - | |
MTX treatment duration (yr), median (range) | 1.0 (0.0-12.4) | - | |
Lag time to biologic therapy initiation (yr), median (range) | 0.3 (0.0-11.3) | - | |
Biologic therapy duration (yr), median (range) | 0.1 (0.0–13.0) | - | |
On therapy (n(%)) | 92.0 (71.0) | - | |
Ongoing therapy (n(%)) | - | ||
• None therapy or drug | 38.0 (29.0) | ||
• Methotrexate | 30.0 (23.0) | ||
• Etanercept | 22.0 (17.0) | ||
• Adalimumab | 26.0 (20.0) | ||
• MTX + Etanercept | 3.0 (2.0) | ||
• MTX + Adalimumab | 3.0 (2.0) | ||
• Other | 2.0 (2.0) | ||
• NSAIDs | 6.0 (5.0) | ||
Number of involved joints at JIA onset, median (range) | 2.0 (0.0–15.0) | - | |
Number of involved joints at the baseline, median (range) | 3.0 (0.0–15.0) | - | |
History of uveitis, n(%) | 28.0 (22.0) | - |